Parkinson's Disease Drugs Market 2020 Global Top Key Players, Emerging Size, Growth Factor, Share- Novartis, Orion Pharma Ltd, ACADIA Pharmaceuticals Inc

(The Express Wire via Comtex)

The globalParkinson's disease drugs marketis likely to grow in the coming years due to the growing emphasis on the treatment of Parkinson's disease. According to a report published by Fortune Business Insights, titled “Parkinson’s Disease Drugs: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 4,500.0 Mn in 2018. Fortune Business Insights states that the market will reach US$ 8,383.2 Mn by 2026, thereby exhibiting a CAGR of 8.1%.

Increasing usage approvals are contributing to the growth of the global Parkinson's disease drugs market. The Food and Drug Administration recently cleared two new drugs for the treatment of Parkinson’s disease. The drug approvals for Rytary and Duopa will emerge as breakthroughs in the healthcare industry.

Request a Sample Copy of the Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/parkinson-s-disease-drugs-market-100655

Leading Players operating in the Parkinson’s Disease Drugs Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Pfizer, Inc.
  • Hoffmann-La Roche Ltd
  • Merck and Co., Inc.
  • Novartis
  • Orion Pharma Ltd
  • UCB S.A
  • Teva Pharmaceutical Industries Ltd.
  • Vertical Pharmaceuticals, LLC
  • ACADIA Pharmaceuticals Inc.
  • Impax Laboratories, Inc.
  • Lundbeck A/S.

AbbVie gets FDA Nod for Orphan Drug ‘Duopa’

The report includes an in-depth analysis of various drug approvals and their effect on the global market. In addition to the clearance for Rytary, the FDA approved another drug in the same year which was also associated with the treatment of Parkinson’s disease. ‘AbbVie’, a pharmaceutical company, announced that it had received approval for the commercialization of its ‘Duopa’. The duopa can be used for treating fluctuations in patients diagnosed with advanced Parkinson's disease. The Duopa was classified as an orphan drug as it is used to treat a rare disease that is affecting fewer than 200,000 people in the United States. Fortune Business Insights has predicted that the aforementioned drug approvals may have a direct impact on the vendor scale. Competitors are likely to be encouraged by the approvals for Parkinson’s disease drugs. This, in turn, is likely to favor growth of the global market in the coming years.

For more information in the analysis of this report, visit:https://www.fortunebusinessinsights.com/industry-reports/parkinson-s-disease-drugs-market-100655

Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
    • Market Trends
  • Key Insights
    • Prevalence of Parkinson's Disease - For Key Countreis, 2018
    • Regulatory Scenario - For Key Countries
    • Patent Snapshot
    • New Product Launch
    • Pipeline Analysis
    • Key Industry Developments - Mergers, Acquisitions and Partnerships
  • Global Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast By Drug Class
      • Decarboxylase Inhibitors
      • Dopamine Agonists
      • Monoamine Oxidase Type B (MAO-B) Inhibitors
      • Catechol-O-Methyltransferase (COMT) Inhibitors
      • Others
    • Market Analysis, Insights and Forecast By Route of Administration
      • Oral
      • Injection
      • Transdermal
    • Market Analysis, Insights and Forecast By Distribution Channel
      • Hospital Pharmacy
      • Retail Pharmacy
      • Online Stores
    • Market Analysis, Insights and Forecast By Region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East and Africa
    • North America Parkinson's Disease Drugs Market Analysis, Insights and Forecast, 2014-2025
      • Key Findings / Summary
      • Market Analysis By Drug Class
        • Decarboxylase Inhibitors
        • Dopamine Agonists
        • Monoamine Oxidase Type B (MAO-B) Inhibitors
        • Catechol-O-Methyltransferase (COMT) Inhibitors
        • Others
      • Market Analysis By Route of Administration
        • Oral
        • Injection
        • Transdermal
      • Market Analysis By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Stores
      • Market Analysis By Country
        • S.
        • Canada

Market Segmentation:

By Drug Class

  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Monoamine Oxidase Type B (MAO-B) Inhibitor
  • Catechol-O-Methyltransferase (COMT) Inhibitors
  • Others

By Route of Administration

  • Oral
  • Injection
  • Transdermal

By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • Middle East and Africa (South Africa, GCC and Rest of Middle East and Africa)

Reasons to Purchase this Report:

  • Comprehensive analysis of the Parkinson’s Disease Drugs Market growth drivers, obstacles, opportunities, and other related challenges.
  • Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
  • Identifies market restraints and boosters.
  • Identifies all the possible segments present in the market to aid organizations in strategic business planning.

Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/parkinson-s-disease-drugs-market-100655

KEY QUESTIONS ANSWERED:

  • What are the key technological and Parkinson’s Disease Drugs Market trends shaping the market?
  • What are the key opportunities in the market?
  • What are the key companies operating in the market?
  • Which company accounted for the highest market share?
  • Why Choose Fortune Business Insights?
  • What is the market size and growth rate of the global and regional market by various segments?
  • What is the market size and growth rate of the market for selective countries?
  • Which region or sub-segment is expected to drive the market in the forecast period?
  • What Factors are estimated to drive and restrain the Parkinson’s Disease Drugs Market growth?

Related Reports:

Disposable Medical Gloves Market

Blood Glucose Monitoring Systems Market

Electrophysiology Devices Market

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:[email protected]

Linkedin|Twitter|BLogs

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Parkinson's Disease Drugs Market 2020 Global Top Key Players, Emerging Size, Growth Factor, Share- Novartis, Orion Pharma Ltd, ACADIA Pharmaceuticals Inc.